Who are AGT4, AGZ's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Edarbi, Cozaar, Candesartan Thiazide, Candemore Plus Tab, olmesartan medoxomil and a diuretic, Stop group.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/agt4-agz.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

AGT4, AGZ — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AGT4, AGZ (AGT4, AGZ) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: angiotensin II receptor blocker. Area: Cardiovascular.

phase 3 angiotensin II receptor blocker AT1 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

AGT4, AGZ (AGT4, AGZ) — Ahn-Gook Pharmaceuticals Co.,Ltd. AGT4 and AGZ are angiotensin II receptor blockers.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AGT4, AGZ TARGET	AGT4, AGZ	Ahn-Gook Pharmaceuticals Co.,Ltd	phase 3	angiotensin II receptor blocker	AT1 receptor
Edarbi	AZILSARTAN MEDOXOMIL	Arbor Pharms Ireland	marketed	Angiotensin 2 Receptor Blocker	AT1 receptor	2011-01-01
Cozaar	losartan	Merck & Co.	marketed	ARB (Angiotensin II receptor blocker)	AT1 receptor	1995-04-14
Candesartan Thiazide	Candesartan Thiazide	Institut de Recherches Cliniques de Montreal	marketed	Angiotensin II receptor blocker / Thiazide diuretic combination	AT1 receptor (angiotensin II type 1 receptor); thiazide-sensitive sodium-chloride cotransporter
Candemore Plus Tab	Candemore Plus Tab	Chong Kun Dang Pharmaceutical	marketed	Angiotensin II receptor blocker / Calcium channel blocker combination	AT1 receptor; L-type calcium channel
olmesartan medoxomil and a diuretic	olmesartan medoxomil and a diuretic	Daiichi Sankyo Co., Ltd.	marketed	Angiotensin II receptor blocker (ARB) + diuretic combination	AT1 receptor (angiotensin II type 1 receptor)
Stop group	Stop group	Asan Medical Center	marketed	Angiotensin receptor blocker	AT1 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-03-26 — Edarbi · 9066936 · US
2030-02-04 — Edarbi · 9169238 · US
2031-07-01 — Edarbi · 9387249 · US

Sponsor landscape (angiotensin II receptor blocker class)

Ahn-Gook Pharmaceuticals Co.,Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AGT4, AGZ — Competitive Intelligence Brief. https://druglandscape.com/ci/agt4-agz. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing